Know Labs Advances Non-Invasive Glucose Monitoring with $12 Million Capital Injection from Lind Global Fund II

Know Labs, Inc. (NYSE American: KNW), the developer of innovative non-invasive medical diagnostic technology, has announced a strategic funding agreement with Lind Global Fund II LP, managed by The Lind Partners, a New York-based institutional investor. The financing structure involves an initial $4 million close from a total commitment of up to $12 million, marking a significant milestone in the company’s journey toward FDA regulatory clearance for its proprietary continuous glucose monitoring device.

Accelerating Core Development Initiatives

The capital influx enables Know Labs to expand operations across four critical development streams. These include advancing hardware engineering, scaling up clinical research data collection, refining proprietary algorithms, and strengthening its intellectual property portfolio around its core radiofrequency dielectric sensor technology.

Ron Erickson, Chief Executive Officer and Chairman, highlighted the strategic importance of this funding round: “This investment positions us to validate our sensor technology in large-scale clinical trials while maintaining momentum toward FDA submission. The non-invasive wearable continuous glucose monitor represents a meaningful shift in how patients can access real-time glucose monitoring without the burden of traditional invasive methods.”

Phillip Valliere, Managing Director at The Lind Partners, expressed confidence in the partnership: “Know Labs has demonstrated consistent execution across development milestones and has constructed a robust intellectual property foundation. We’re confident in the company’s management team and its potential to achieve regulatory approval and build strategic partnerships.”

Investment Structure and Financial Terms

Know Labs received net proceeds of approximately $3.68 million after fees from the initial $4 million close. The funding takes the form of convertible secured notes with an aggregate face value of $14.4 million against the $12.0 million purchase price.

The convertible note from this initial close carries specific conversion terms. It features a 24-month maturity and offers a conversion price of $1.00 per share—representing a 50% premium to the previous closing price of $0.667. The company retains flexibility on payment: repayment can be made in cash or through share issuance priced at 90% of the average of the three lowest daily VWAPs during the 20 trading days before payment.

Additionally, Know Labs will issue to Lind a warrant to purchase 3,000,000 shares, with warrant coverage at 75% of the funded amount. The warrant carries a $0.80 per share exercise price (20% premium to the historical closing price) and remains exercisable for 60 months following the six-month period after initial funding.

Repayment Flexibility and Asset Security

Beginning 120 days after the funding date, Know Labs will repay principal through monthly installments of $240,000 (representing 1/20th of the face value). The company has the flexibility to satisfy these repayments through cash payments plus a 5% fee, common stock issuance, or a combination of both approaches.

Lind retains the right to increase two monthly repayments to as much as $750,000 if paid in equity. All funding is secured by assets held by Know Labs and its subsidiary entities. The New York Stock Exchange American has approved both the funding agreement and the issuance of related securities. Benchmark Company, LLC served as exclusive financial advisor for this transaction.

Technology Platform and Market Opportunity

Know Labs’ core technology employs spectroscopy and electromagnetic energy to capture unique molecular signatures from substances. This patented and patent-pending approach can be adapted to wearable, mobile, or laboratory-based devices. The first commercial application targets continuous glucose monitoring, enabling patients to access affordable, real-time blood glucose data without invasive procedures. The product will require FDA clearance before market launch.

About The Lind Partners

The Lind Partners manages institutional growth capital funds investing in small- and mid-cap companies across the US, Canada, Australia, and the UK. Since 2011, the firm has completed over 200 direct investments totaling more than $2 billion in transaction value, typically deploying between $1 million and $30 million per investment.